Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Офтальмология / Английские материалы / Drug Product Development for the Back of the Eye_Kompella, Edelhauser_2011.pdf
Скачиваний:
0
Добавлен:
28.03.2026
Размер:
13.01 Mб
Скачать

232

R. Herrero-Vanrell

Mw

Weight-average molecular weight

Mn

Number-average molecular weight

PEG

Polyethylene glycol

kGy

Kilo Gray

Tg

Glass transition temperature

Tm

Crystalline melting points

Css

Steady state concentration

K0

Zero-order constant

Vd

Volume of the vitreous

Ke

Elimination rate constant

G

Gauge

PBS

Phosphate buffer solution

BSS

Buffer solution

HA

Hyaluronic acid

HPMC

Hydroxypropylmethyl cellulose

AUC

Area under the curve

5-FU

5-fluorouracil

VEGF

Vascular Endothelial Growth Factor

AMD

Age macular degeneration (AMD)

TA

Triamcinolone acetonide

PVR

Proliferative vitreoretinopathy

RPE

Retinal pigment epithelium

RD

Retinal detachment

RA

Retinoic acid

LPS

Lipopolysaccharide

TRD

Tractional retinal detachment

CyS

Cyclosporine

CNV

Choroidal neovascularization

ARN

Acute retinal necrosis

HSV

Herpes simplex virus

Da

Daltons

CMV

Cytomegalovirus

HCMV

Human cytomegalovirus

RGC

Retinal ganglion cells (RGC)

ECM

Extracellular matrix

MMP2

Matrix metalloproteinase

RPCs

Retinal progenitor cells (RPCs)

10.1  Introduction

Successful ophthalmic therapy requires effective concentrations of the drug in the target site. Therapeutic concentrations of the active substance in cornea and conjunctiva are mandatory for the treatment of ocular surface diseases such as dry eye syndrome, surface inflammation, or infection. However, if the drug has to reach the

10  Microparticles as Drug Delivery Systems for the Back of the Eye

233

aqueous humor as it is the case of hypotensive agents for glaucoma management, the active substance must be present at high concentrations at the site of administration to cross through the cornea and/or conjunctiva to achieve therapeutic concentrations in the anterior segment (only 5% of the administered dose penetrates the cornea) (Maurice and Mishima 1984). Furthermore, the drug must have specific physical and chemical properties to cross the ocular surface barriers. While lipophilic drugs cross the epithelium well, hydrophilic substances are able to cross the stroma. In any case, the molecular weight of the substance must be small enough to use the transcellular or paracellular route to reach intraocular structures.

In the management of vitreoretinal disorders, the drug must reach the back of the eye. In these cases, periocular, intravitreous, or other intraocular injections are required. If successive administrations are needed, special care has to be taken to avoid fibrosis and inflammation at the site of injection. Moreover, it is well known that repeated intravitreal injections are poorly tolerated and the risk of adverse effects (e.g., cataracts, intravitreal hemorrhages, and retinal detachment) increases with the number of administrations (Herrero-Vanrell and Refojo 2001).

Controlled drug delivery systems can maintain concentrations of the active substance at the target site for long periods of time. Among them, implants (>1 mm), microparticles (1–1,000 mm), and nanoparticles (1–1,000 nm) have been developed for the treatment of posterior segment pathologies (Herrero-Vanrell and Refojo 2001; Urtti 2006) (Fig. 10.1).

Fig. 10.1Strategies to avoid frequent intraocular injections. “Depot” systems – Poor aqueous soluble drugs. Once injected, the active substance is slowly dissolved in the vitreous. Drug delivery systems (DDS): Implants, microparticles, and nanoparticles. Biodegradable DDSs disappear from the site of administration after delivering the drug

234

R. Herrero-Vanrell

Fig. 10.2Administration routes of microparticles: Intravitreal, subretinal, and periocular

Microparticles are adequate for the intraocular route, bypassing the blood–­ocular barrier. One of their advantages is that microparticles can release the drug over the time with one single administration, having the same effect than multiple injections (Fig. 10.2). Furthermore, injection of microparticles is carried out as a conventional suspension.

Microparticles are usually prepared with a polymer or mixture of polymers and one or several active substances. Depending on the nature of the polymer (erodible or biodegradable and nonerodible or nonbiodegradable) microparticles remain or disappear from the site of injection after delivering the drug. In the case of posterior segment diseases, biodegradable microparticles are preferred.

Microparticles are capable to provide sustained and controlled release of the bioactive agent, while the remaining drug still present inside the particle is protected from degradation and physiological clearance.

By physical structure, microparticles are classified in microcapsules and microspheres. Microcapsules are constituted by a drug core, which is surrounded by a polymer layer (reservoir structure). Conversely, in the microspheres the drug is dispersed through the polymeric network (matrix structure) (Fig. 10.3).

Among the biodegradable polymers employed to prepare microparticles are gelatin, albumin, polyorthoesters, polyanhydrides, and polyesters (Colthrust et al. 2000; Herrero-Vanrell and Refojo 2001). Since several years ago, the most employed polymers to prepare biodegradable microspheres are the poly(lactic) acid (PLA), poly(glycolic) acid (PGA), and their copolymers poly(lactic-co-glycolic) acid (PLGA). PLA and PGA have crystalline structure whereas PLGA is amorphous. Experience has shown that the PLGA 50:50 (50% lactide and 50% glycolide) degrades relatively fast to metabolic lactic and glycolic acid that are readily eliminated from the body after suffering metabolism to carbon dioxide and water mediated by Krebs cycle (Zimmer and Kreuter 1995). Regarding to molecular weight, polymers with small chains degrade faster than high molecular weight polymers. For the back of the eye, PLA and PLGA polymers have been employed to prepare different devices: implants, scleral plugs, pellets, discs, films, and rods (Yasukawa et al. 2004; Mansoor et al. 2009).

10  Microparticles as Drug Delivery Systems for the Back of the Eye

235

Fig. 10.3Structure of microparticles. Microcapsules (reservoir system) and microspheres (matrix structure)

10.2  Manufacturing of Microparticles

Manufacturing of microparticles are mainly based on four basic techniques: aggregation by pH adjustment or heat, coacervation (phase separation), spray drying, and solvent extraction/evaporation (Freitas et al. 2005). Coacervation required the use of solvents and coacervating agents that can remain in the microparticles once prepared and low micrometer size is difficult to obtain. The use of supercritical gases as phase separating agents has been introduced to avoid potentially harmful residues in the microspheres. Spray drying is relatively simple but not useful for highly tem- perature-sensitive drugs. Microspheres prepared according to this technique are highly porous. Microspheres loaded with triamcinolone acetonide (TA) and ciprofloxacin have been prepared by the spray drying technique for intraocular injection (Paganelli et al. 2009).

The most commonly reported technique for microspheres formation is the solvent extraction/evaporation method (evaporation of a solvent from an emulsion) (Herrero-Vanrell et al. 2000; Amrite et al. 2006) (Fig. 10.4). It requires a dissolution or dispersion of the active substance in a first solvent containing the matrix forming polymer (inner phase). After that, an emulsification of the polymer organic solution in a second continuous phase immiscible with the inner phase is carried out. Then, an extraction of the organic solvent from the formed emulsion by evaporation is

236

O/W emulsion

Drug

O-phase:

PLGA solution

Drug (dissolved)

in CH2CI2

+PLGA solution

 

in CH2CI2

S/O/W emulsion

R. Herrero-Vanrell

 

Dissolved

 

drug

Addition of

O/W emulsion

aqueous-phase

 

(PVA 2% in H2O)

 

 

 

 

Solid

 

 

 

drug

PLGA solution

O-phase:

Addition of

S/O/W emulsion

in CH2CI2

drug (solid) +

aqueous-phase

 

 

PLGA solution

(PVA 2% in H2O)

 

 

in CH2CI2

 

 

Preparation of drug dispersion

Solid

Sonication

Homogeneous

drug

drug solid

 

↓Ta (ice)

dispersion

 

↓t(30")

 

 

↓power

 

Fig. 10.4Schematic procedure for microspheres preparation according to solvent/extraction/ evaporation technique (O/W emulsion and S/O/W emulsion) O/W emulsion – The drug is dissolved in the inner phase of the emulsion S/O/W emulsion – The drug is suspended as solid in the inner phase of the emulsion

performed at room temperature or under vacuum. Finally, the immature microspheres are harvested and dried before freeze-drying or desiccation. Lyophilization is preferred because the stability of the product increased. Depending on the solubility of the drug, oil in water (O/W) or oil in oil (O/O) emulsions are formed. In the case of aqueous soluble drugs an (O/O) emulsion achieves higher encapsulation efficiencies. By the contrary, for poor soluble drugs the O/W emulsion technique

Соседние файлы в папке Английские материалы